CPT code 0668U: Pancreatic cancer assay, 5hmC and glycan analysis2026 Medicare lab fee · Clinical Laboratory Fee Schedule
This blood-based pancreatic oncology assay combines DNA sequencing with 5hmC enrichment and glycan analysis to report cancer detected or not detected.
Medicare has no national amount for 0668U: it’s on the 2026 Clinical Laboratory Fee Schedule as contractor-priced, so each Medicare Administrative Contractor sets the payment.
Medicare lab fee · CLFS 2026 Q4
Contractor-priced (CLFS indicator L)
Set by your MAC
CMS lists 0668U on the Clinical Laboratory Fee Schedule without a national amount: each Medicare Administrative Contractor prices it for its jurisdiction.
- National amount
- None
- Priced by
- Each MAC
- Fee schedule
- Clinical lab
- CMS updates
- Quarterly
The contractor that processes the claim sets the amount for its jurisdiction. Patients usually owe no Part B deductible or coinsurance for covered clinical lab tests.
On this page 6 sections
What 0668U covers
This proprietary laboratory assay evaluates whole blood or plasma for pancreatic oncology markers. It combines genome sequencing with 5-hydroxymethylcytosine (5hmC) enrichment and glycan biomarker analysis. An algorithm reports the result as cancer detected or not detected. The code identifies this particular combined molecular and glycan analysis rather than an individual serum tumor-marker measurement. Laboratories report the assay result for pancreatic oncology testing.
Report 0668U for the described assay using whole blood or plasma. The code was added to the CLFS effective October 1, 2026. Medicare pays it through the CLFS, with local pricing: each Medicare Administrative Contractor sets the payment. The code has no physician fee schedule payment row, so there is no separately listed physician interpretation payment under that schedule.
This summary was written with AI assistance from CMS Clinical Laboratory Fee Schedule data. Amounts on this page come directly from CMS files.
How Medicare pays 0668U
Clinical lab tests aren’t priced like physician services. They’re paid from their own fee schedule, with its own rules. See the whole lab fee schedule.
Priced by each contractor
0668U carries CLFS indicator L: CMS publishes no national amount, and each Medicare Administrative Contractor sets the payment for its jurisdiction. Ask your MAC for its current amount.
No office or facility rate
Lab tests aren’t built from relative value units, so there’s no office and facility split: the place of service doesn’t change the CLFS amount.
Updated every quarter
CMS republishes the CLFS each quarter. New tests, often proprietary laboratory analyses (PLA codes), join during the year; existing amounts are updated each January.
Not on the physician fee schedule
The physician fee schedule doesn’t list 0668U: Medicare pays the test only from the CLFS.
0668U compared with similar tests
- 86301CA 19-9Quantitative tumor antigen$20.81
- This code is for CA 19-9 testing, which measures a tumor-associated antigen. 0668U is the combined pancreatic DNA, 5hmC, and glycan assay with an algorithmic result.
- 82378CEA testProtein level$18.96
- This code is for carcinoembryonic antigen testing. It measures a single tumor marker, unlike 0668U’s combined genomic and glycan analysis.
0668U billing questions
Which specimen is associated with 0668U?
The assay uses whole blood or plasma. Report the code for this specific DNA, 5hmC, and glycan analysis.
How does 0668U differ from CA 19-9 testing?
0668U combines genomic, 5hmC, and glycan signals and reports a cancer-detected or not-detected result. CA 19-9 testing measures a tumor-associated antigen.
Does Medicare pay a separate physician interpretation for 0668U?
The code has no physician fee schedule payment row and is paid through the CLFS.
How is Medicare payment set for this code?
It is locally priced under the CLFS. Each Medicare Administrative Contractor sets the payment.
Where this amount comes from
FeeBase reads lab amounts directly from the CMS Clinical Laboratory Fee Schedule file for the quarter: one row per code, with its payment indicator and national amount. Contractor-priced tests are labeled, never given a made-up amount. Amounts are Medicare payment limits, not a patient’s bill or a commercial rate.
CMS CLFS 2026 Q4 · effective Oct 1, 2026 through the day before Jan 1, 2027
Show the CMS file line behind this amount
Fee sheets · Coming soon
Put 0668U and the rest of your codes on one sheet
Your codes at your locality, with payer contracts beside Medicare.
Join the waitlist